ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Invesco Nasdaq Biotechnology ETF
34.69
-0.4365
-1.24%
盤後:
35.39
0.7007
+2.02%
18:06 EDT
成交量:
2.55萬
成交額:
88.51萬
市值:
9,643.63萬
市盈率:
- -
高:
35.13
開:
35.13
低:
34.63
收:
35.13
52周最高:
36.84
52周最低:
23.42
股本:
278.00萬
流通股本:
278.00萬
量比:
1.14
換手率:
0.92%
股息:
0.26
股息率:
0.74%
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
Tozorakimab在OBERON和TITANIA兩項Ⅲ期臨床試驗中,在降低慢阻肺病急性加重方面均顯示出統計學和臨床意義上的顯著改善
美通社
·
09/08
兩項驗證性試驗迎突破性結果!阿斯利康Tozorakimab再傳好消息
上观新闻
·
09/08
更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標
路透中文
·
09/08
安進Phase 3 Dellphi-305研究重大突破:總生存期獲益顯著優於度伐利尤單抗單藥治療
美股速递
·
09/08
Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善
美股速递
·
09/08
BMO下調安進及BioNTech評級至「與大市同步」
格隆汇
·
09/08
苑東生物:公司將於9月16日參加科創板2026年半年度創新藥行業集體業績説明會
证券日报
·
09/08
禮邦醫藥-B(09637):AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准
智通财经
·
09/08
美股盤前|英特爾、甲骨文升逾4%;諾華重挫12%,IONIS下跌10%;阿斯麥新一代EUV光刻機獲台積電和三星使用承諾
老虎资讯综合
·
09/08
AI 製藥迎來價值兑現期,創新藥產業打開全新增長空間
独角兽智库
·
09/08
PHARVARIS的3期臨床試驗達到全部主要及次要終點。
智通财经
·
09/08
石藥集團:SYH2083滴眼液獲臨床試驗批准
智通财经
·
09/08
膽固醇藥物臨床試驗受挫,數十億美元研發競賽蒙上陰影
环球市场播报
·
09/08
諾華試驗受挫且BMO下調評級,安進股價下跌
路透中文
·
09/08
復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准
智通财经
·
09/08
盤前異動:安進、耐克、Bloom Energy 等個股受關注
投资观察
·
09/08
美股異動|安進盤前跌5.4%,諾華同靶點藥物III期臨床失敗,Lp(a)賽道遭重創
中金财经
·
09/08
製藥巨頭諾華股價大跌近10%,遭遇三項藥物臨床試驗受挫
环球市场播报
·
09/08
安進股價盤前下跌5.4%;競爭對手諾華的膽固醇藥物後期臨床試驗失敗。
智通财经
·
09/08
邁普醫學(301033.SZ):「可吸收止血流體明膠」進入臨床試驗階段
智通财经
·
09/08
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IBBQ/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.6893,"timestamp":1789761600000,"preClose":35.1258,"halted":0,"volume":25483,"hourTrading":{"tag":"盘后","latestPrice":35.39,"preClose":34.6893,"latestTime":"18:06 EDT","volume":10,"amount":347.71652000000006,"timestamp":1789769186640,"change":0.7007,"changeRate":0.020199,"amplitude":0.020199},"delay":0,"changeRate":-0.012426763233862154,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"盤後交易","change":-0.4365,"latestTime":"09-18 18:55:20 EDT","open":35.13,"high":35.13,"low":34.6296,"amount":885120.711876,"amplitude":0.014246,"askPrice":52.1,"askSize":100,"bidPrice":32.86,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789776000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":35.1258,"sharesOutstanding":2520001,"nav":34.34966,"aum":95492089.14966,"dividendRate":0.007406,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.39,"preClose":34.6893,"latestTime":"18:06 EDT","volume":10,"amount":347.71652000000006,"timestamp":1789769186640,"change":0.7007,"changeRate":0.020199,"amplitude":0.020199},"volumeRatio":1.139272,"impliedVol":0.0457,"impliedVolPercentile":0.0199},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.139272,"shares":2780001,"dividePrice":0.2569,"high":35.13,"amplitude":0.014246,"preClose":35.1258,"low":34.6296,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.6893,"committee":0.333333,"eps":0,"divideRate":0.007406,"volume":25483,"delay":0,"ttmEps":0,"open":35.13,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.472,"twentyDayClose":35.8,"sixtyDayClose":31.2119},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665968376","title":"Tozorakimab在OBERON和TITANIA兩項Ⅲ期臨床試驗中,在降低慢阻肺病急性加重方面均顯示出統計學和臨床意義上的顯著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2665968376","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665968376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:18","pubTimestamp":1788873480,"startTime":"0","endTime":"0","summary":"OBERON和TITANIA两项Ⅲ期试验的结果令人鼓舞,证实tozorakimab在广泛患者人群中均能降低急性加重风险,有望帮助患者摆脱反复急性加重的困扰,获得全新的治疗选择。Tozorakimab 是首个在广泛慢阻肺病患者人群中显示出减少气道黏液栓堵塞作用的生物制剂3。Tozorakimab总体耐受性和安全性良好,唯一报告的药物不良反应为注射部位反应1,2。目前,tozorakimab已在欧盟、中国等主要市场进入上市许可审评阶段,用于治疗慢性阻塞性肺疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0708994859.HKD","PSYK","LU0109394709.USD","MDTX","LU0058720904.USD","BK4588","AZN","BK4585","LU0128525929.USD","IBBJ","LU0432979614.USD","LU0320765992.SGD","LU0029864427.USD","LU2089984988.USD","LU2237443549.SGD","LU2462157665.USD","BK4568","LU1267930573.SGD","LU1829250122.USD","LU0289739699.SGD","BK4007","LU2417539215.USD","AZNH","IE00B3T34201.USD","LU0889565916.HKD","LU2237443622.USD","LU2468319806.SGD","LU2236285917.USD","IBBQ","LU2237443978.SGD","LU2237443465.HKD","LU2456880835.USD","LU2237443382.USD","LU2237443895.HKD","LU0310800379.SGD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665137530","title":"兩項驗證性試驗迎突破性結果!阿斯利康Tozorakimab再傳好消息","url":"https://stock-news.laohu8.com/highlight/detail?id=2665137530","media":"上观新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665137530?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:14","pubTimestamp":1788873273,"startTime":"0","endTime":"0","summary":"慢性阻塞性肺疾病候选药物Tozorakimab再度传来好消息:其在最新两项验证性试验中都展示出了突破性结果,有望为全球数百万接受标准吸入治疗后仍面临急性加重风险的患者带来新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868309733.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868309733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","BEZ","BEX","BEC","BEG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732793","title":"更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732793","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732793?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:14","pubTimestamp":1788873260,"startTime":"0","endTime":"0","summary":"阿斯利康抗癌药物组合在晚期临床试验中达到主要生存目标路透9月8日-阿斯利康(AstraZeneca)AZN.L周二表示,其抗癌药物Imfinzi与安进(Amgen)的AMGN.O靶向免疫疗法Imdelltra联合使用,在一项晚期临床试验中,显著提高了广泛期小细胞肺癌一线治疗患者的总生存期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S450114:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU2355687059.USD","BK4599","LU1170363599.USD","PJP","LU1046234339.USD","TBXU","AMGN","BK4139","LU1880407132.USD","LU2091194634.USD","LU0784383803.USD","LU2279689827.SGD","LU0661504455.SGD","LU0889566641.SGD","LU0545039389.USD","IBBQ","LU0029864427.USD","LU0203347892.USD","LU0969580561.USD","IE0034235188.USD","IBB","LU1829250122.USD","LU0957799991.USD","03165","LU1481599808.USD","LU1863844749.USD","LU0827474353.SGD","AZN.UK","LU1061106388.HKD","LU2237443465.HKD","LU0920783379.SGD","LU1487256676.USD","LU0109394709.USD","BBH","LU2242652126.USD","LU1003076772.USD","LU1923622614.USD","LU0882574055.USD","LU0058720904.USD","LU0077335932.USD","LU0997586515.USD","LU1084165304.USD","PBE","LU1023059063.AUD","LU0526926950.USD","LU2433249047.HKD","LU0122379950.USD","BIB","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115495471","title":"安進Phase 3 Dellphi-305研究重大突破:總生存期獲益顯著優於度伐利尤單抗單藥治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1115495471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115495471?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:07","pubTimestamp":1788872830,"startTime":"0","endTime":"0","summary":"安进公司宣布,其Phase 3 Dellphi-305临床研究取得重大成果——与度伐利尤单抗单独用药相比,该疗法在总生存期上展现出显著且具有临床意义的改善。这一里程碑式的发现,无疑为肿瘤治疗领域注入了新的活力与希望。尽管完整的详细数据尚未全面披露,但安进方面表示,其临床意义及安全性特征将在即将召开的重大学术会议上进行详尽报告。安进公司并未止步于此。随着研发管线的持续推进,安进正逐步兑现其以创新疗法攻克严重疾病的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","LU0122379950.USD","LU2112291526.USD","BK4599","BK4585","LU2468319806.SGD","TBXU","LU2242652126.USD","BK4581","PJP","LU2242646821.SGD","IE00B2B36J28.USD","BK4534","IE00BFTCPJ56.SGD","AMGN","BK4139","LU0889565916.HKD","IE00B4R5TH58.HKD","BK4533","LU0868494617.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4566","LU0109394709.USD","LU0320765992.SGD","LU1061106388.HKD","LU1057294990.SGD","LU0289739699.SGD","LU1983299246.USD","IE0009355771.USD","SG9999001440.SGD","BK4588","LU0058720904.USD","IE0002141913.USD","IBBQ","BIB","LU1023059063.AUD","LU1571399168.USD","BBH","IBB","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109517247","title":"Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1109517247","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109517247?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:04","pubTimestamp":1788872687,"startTime":"0","endTime":"0","summary":"Imdelltra®与Imfinzi®的联合疗法,于一线广泛期小细胞肺癌治疗领域,取得了具有划时代意义的总生存期提升。这一突破性进展,不仅为患者带来了新的曙光,也重塑了该领域的治疗格局。从数据层面观察,联合治疗方案的生存获益尤为显著,堪称里程碑式的成就。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","IE00B2B36J28.USD","BK4533","TBXU","BK4588","LU1061106388.HKD","BIB","LU0889565916.HKD","LU1571399168.USD","LU0289739699.SGD","IE0002141913.USD","IBB","PJP","BK4534","SG9999001440.SGD","BK4566","LU0122379950.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","IBBQ","IE0009355771.USD","LU1983299246.USD","LU0058720904.USD","LU0109394709.USD","BK4581","LU0320765992.SGD","LU2242652126.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU1023059063.AUD","BK4599","LU0868494617.USD","LU2089984988.USD","PBE","AMGN","BK4139","LU2112291526.USD","IE00BJT1NW94.SGD","BBH","BK4585","LU2242646821.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665387373","title":"BMO下調安進及BioNTech評級至「與大市同步」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665387373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665387373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:59","pubTimestamp":1788872377,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4581","LU1061106388.HKD","LU2468319806.SGD","BIB","BK4599","IE0002141913.USD","AMGN","BK4534","IE00BFTCPJ56.SGD","LU0289739699.SGD","LU2112291526.USD","LU0320765992.SGD","LU1023059063.AUD","IBBQ","LU0868494617.USD","LU0889565916.HKD","IBB","BK4585","IE0009355771.USD","BK4566","PJP","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU2089984988.USD","BBH","LU1571399168.USD","TBXU","LU2242646821.SGD","LU1057294990.SGD","LU0109394709.USD","LU2242652126.USD","PBE","BK4139","IE00BJT1NW94.SGD","BK4533","LU0058720904.USD","LU0122379950.USD","IE00BJJMRZ35.SGD","LU1983299246.USD","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378020","title":"苑東生物:公司將於9月16日參加科創板2026年半年度創新藥行業集體業績説明會","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378020","media":"证券日报 ","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378020?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:16","pubTimestamp":1788869760,"startTime":"0","endTime":"0","summary":"9月8日,苑东生物发布公告称,公司将于9月16日参加科创板2026年半年度创新药行业集体业绩说明会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircrnn9176436.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircrnn9176436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK0239","BK1574","KSTR","MEDX","BK1161","688513","LNGR","IBBQ","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320617","title":"禮邦醫藥-B(09637):AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320617?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788869000,"startTime":"0","endTime":"0","summary":"智通财经APP讯,礼邦医药-B 发布公告,公司近日就AP308的新药临床试验申请获美国食品药品监督管理局批准,将启动一项AP308用于治疗IgA肾病的首次人体临床试验。就公司所知,AP308为首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。该平台具有优异的稳定性及成药性,并可在保留蛋白酶对IgA1高效切割活性的同时,显著延长药物体内半衰期、降低肾脏清除并减弱免疫原性,为长效、低频次给药奠定基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","159938","09939","BK1191","BMED","MDTX","BK1515","BK1574","BK1161","IBBJ","09637","159151","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103332998","title":"美股盤前|英特爾、甲骨文升逾4%;諾華重挫12%,IONIS下跌10%;阿斯麥新一代EUV光刻機獲台積電和三星使用承諾","url":"https://stock-news.laohu8.com/highlight/detail?id=1103332998","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103332998?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868860,"startTime":"0","endTime":"0","summary":"9月8日美元指数上升0.0364%,报98.96。03 要闻1. 三大芯片厂全面采购ASML最先进High NA EUV光刻机以扩产高端制程。ASML确认三星、台积电与英特尔已承诺在2028–2030年起量产使用High NA设备,并与ASML签订光罩尺寸升级合作协议,助力降低AI芯片制造成本。","market":"sg","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1992135399.USD","FENY","LU0654597011.USD","LU0431992006.USD","LU0353189763.USD","LU0124676726.USD","LU0175139822.USD","LU2498475776.HKD","INTC","LU0211327993.USD","LU0081259029.USD","LU0444971666.USD","LU0689626769.HKD","LUMA","LU2237443622.USD","LU1582987597.SGD","OZEM","DDM","LU2242646821.SGD","LU1935043536.SGD","IE00BLSP4239.USD","IYE","INTW","LU1003077747.HKD","OILT","LU1508157978.USD","LU0345770993.USD","LU0742534661.SGD","CHPX","LU0889565833.HKD","LU2242649171.HKD","FCG","LU0889565916.HKD","LU0098860793.USD","LU0878866978.SGD","LU1803068979.SGD","LU2663582299.SGD","LU0321505868.SGD","ESIM","LU1074936037.SGD","IE00BYQQ9H92.USD","BK4097","LU0444973449.USD","BK4512","LU0109392836.USD","LU0203345920.USD","LU0496365809.HKD","LU2746668974.SGD","LU0048573561.USD","TNGY","LU0052756011.USD","LU1582987324.SGD","LU2471134796.USD","LU0965509101.SGD","LU1861220033.SGD","LU0488056044.USD","HK0000304797.USD","BK4007","BK4543","CGDG","LU0345774391.USD","LU2505996509.AUD","DBEF","BK4157","DRIV","LU0368265418.SGD","LU1791710582.SGD","LU2360106780.USD","LU2322448957.HKD","LU0976567544.SGD","LU1691799644.USD","LU2211814178.USD","BK7104","LU0072461881.USD","BBH","BK4570","IE0004445239.USD","LU2326559502.SGD","LU1548497426.USD","LU0868494708.USD","LU0122376428.USD","LU0683600562.USD","IE0002270589.USD","LU1066053197.SGD","LU1623119135.USD","LU2054465674.USD","IE000WAW04H5.SGD","LU1934455194.USD","CHPS","LU2092937221.SGD","LU1718418525.SGD","BK4515","KNOW","IE00BMPRXR70.SGD","LU2506951875.HKD","BK4139","LU2360032135.SGD","ADVE","PPH","LU0274383776.USD","LU0553294199.USD","BK4503","BK4578","LU1934455277.USD","RSPG","SG9999001424.SGD","IXC","LU0541502299.USD","LU1066051498.USD","LU1069347547.HKD","IEFA","EPAI","LU2430703095.HKD","LU2357305700.SGD","LU0310800965.SGD","IGV","THNR","LU2237957811.SGD","LU0320765646.SGD","LU2506952170.USD","LU0289960550.SGD","LU2491050154.USD","LU1582986433.USD","BK4602","IE000MB6IJN5.SGD","IE00BMPRXQ63.HKD","IE00BFTCPJ56.SGD","BK4527","AIQ","IE00B19Z4B17.USD","LU2471134879.HKD","HYDR","LU1282649067.USD","LU0208291251.USD","LU1291159041.SGD","LU2133065610.SGD","DBEU","BK4548","LU0823414478.USD","LU2491050071.SGD","LU2506951792.HKD","TEXU","BK4588","FOTO","LU1720051108.HKD","LU1037948541.HKD","LU2543165471.USD","SG9999001176.USD","LU0130103400.USD","LU0957791311.USD","LU1506573853.SGD","IE00BQXX3C00.GBP","LU2129689514.USD","ORCZ","LU1852331112.SGD","LU2430703178.SGD","LU0149725797.USD","LU1489326972.SGD","LU2473716301.USD","LU2430703251.USD","LU0058720904.USD","LU2108987350.USD","LU1061106388.HKD","SG9999001440.SGD","GNOM","BK4023","LU0432979614.USD","LU0314106906.USD","OGIG","LU0823417653.USD","LU2764263039.SGD","LU2360108059.USD","LU2265009873.SGD","BK4213","LU0162691827.USD","LU0238689110.USD","NVS","SGXZ57979304.SGD","LU0957808578.USD","LU1429558221.USD","SDOW","AVEM","LU0541501648.USD","LU0128525689.USD","LU2125154935.USD","CQTM","DOG","LU0823421333.USD","LU0612318385.USD","LU0823039010.USD","LU1435385759.SGD","LU2720916845.USD","SG9999011175.SGD","LU0170899867.USD","LU2324357040.USD","LU2954938101.SGD","ERX","LU1778281490.HKD","BK4148","IE00BJT1NW94.SGD","BGIA","BK4559","LU1211504680.USD","LU0882747503.HKD","LU0048584097.USD","LU0130517989.USD","BK4579","SOXX","IE00B4R5TH58.HKD","LU0359201612.USD","LU2129689605.HKD","CGNG","LU0072462343.USD","LU0109394709.USD","LU2249611893.SGD","LU0234570918.USD","IBBQ","LU2237957902.USD","IE0004091025.USD","LU0528227936.USD","BK4538","FENI","LU0211326755.USD","IE00B1XK9C88.USD","BK4534","IE0004086264.USD","LU2087621335.USD","BK4592","IE00BHPRN162.USD","LU1935042991.SGD","IE0009355771.USD","LU2244417387.USD","LU2750360997.AUD","IE00B3M56506.USD","LU1267930227.SGD","LU0466842654.USD","CGIC","LU2347655156.SGD","BK4581","LU2272731782.SGD","LU2250418816.HKD","LU1935043023.USD","LU2764263203.CNY","BIB","INT","BK4170","LU0256863811.USD","LU1732799900.SGD","LU0300736492.USD","IE00BWXC8680.SGD","IE0034235303.USD","LU0345769631.USD","LU1430594728.SGD","LU0138981039.USD","LU0642271901.SGD","LU1732800096.USD","LU1585245621.USD","LU2362540622.SGD","LU1917777945.USD","FDTX","LU2023250504.SGD","LU2237443978.SGD","HK0000304805.HKD","ASMH","LU0157215616.USD","LU0630314457.HKD","AVSE","LU2362541273.HKD","SG9999001176.SGD","IE00B5TLWC47.USD","BK4612","BK4575","BK4535","LU0251142724.SGD","LU0417517546.SGD","LU2602419157.SGD","LU1162221912.USD","IE00B5949003.HKD","LU0795875169.SGD","LU1048588211.SGD","LU1720051017.SGD","LU2471134523.USD","LU0965509283.SGD","INYY","LU0912757837.SGD","IBB","DRLL","03165","IE00BZ1G4Q59.USD","LU0823416689.USD","LU0266013472.USD","LU0316494557.USD","LU1235294995.USD","LU0154245756.USD","LU0359202008.SGD","LU1430597077.USD","BK4608","GXPE","EMC","WEEI","LU0823414551.USD","SG9999014567.USD","LU2458330169.SGD","LU0612318971.USD","LU0266512127.USD","CRAK","LU0187121727.USD","PBE","LU2089283258.USD","QQQA","XLE","LU1023059063.AUD","LU1868838027.USD","SPY","LU1150488218.USD","LU0154245673.USD","IE00BQXX3F31.USD","SMH","LU0128526141.USD","SG9999015341.SGD","TTEQ","SG9999002232.USD","SGXZ99366536.SGD","BK4505","LU1150488135.SGD","LU0456854461.SGD","IE00B2Q91V27.USD","LU1868837722.USD","LU2112291526.USD","IE00BSNM7G36.USD","LU0545039389.USD","IE00BD6J9T35.USD","AVXC","LU0158827948.USD","LU2357125470.USD","BK7095","HBMX","LU0882574055.USD","FFGX","LU1935042215.USD","LU0154236417.USD","LU1674673428.USD","BK4533","BLOX","ILOW","LU0477156953.USD","GNMX","LU1057294990.SGD","LU2236285917.USD","IE00BQXX3D17.EUR","BAI","BK4504","LU0985489474.SGD","LU2111349929.HKD","LU0321505439.SGD","LU0143551892.USD","BK4529","IE0002141913.USD","CWI","IE00B19Z3581.USD","TBXU","LU0878005551.USD","LU0070217475.USD","LU1153585028.USD","LU0320765489.SGD","LU2264538146.SGD","LU0348723411.USD","LU1201861165.SGD","SG9999015358.SGD","LU0267386448.USD","SG9999003800.SGD","LU0323591593.USD","LU1023057109.AUD","AIS","LU2931357623.SGD","LU2491049909.HKD","LU2999663052.SGD","LU2290526834.HKD","LU1046421795.USD","LU0792757196.USD","LU1989764748.USD","LU0738911758.USD","DXD","LU0823421416.USD","LU0889566641.SGD","LU1201861249.SGD","LU0234572021.USD","LU1267930490.SGD","LU0122379950.USD","BK4599","LU0203347892.USD","LU0211331839.USD","LU1035773651.USD","LU2089985449.USD","LU0198837287.USD","LU0572939691.SGD","LU2471134952.CNY","UMMA","LU0251131958.USD","ORCS","VDE","IE0031619046.USD","LU0011850046.USD","LU0320765992.SGD","LU2089284900.SGD","SG9999000418.SGD","LU0070302665.USD","IE00B7SZL793.SGD","LU0859254822.USD","IE00BKPKM429.USD","LU2271345857.HKD","BK4605","LU0143863198.USD","DIG","LU1734074674.USD","CNAV","LU1093756168.USD","LU2506951958.HKD","LU2272731600.USD","WUGI","CHAT","IE00BFXG0V08.USD","IE00BLSP4452.SGD","LU0788109394.HKD","LU0950375773.USD","IE0000B7K699.USD","IE0009356076.USD","LU0942090050.USD","LU0965509010.AUD","IE00BMPRXN33.USD","LU1791710400.SGD","IE00B2B36J28.USD","LU0345780950.USD","LU0861579265.USD","DIA","CGGO","LU0949170772.SGD","LU1267930813.SGD","LU0211326839.USD","LU2211815571.USD","BK4591","LU2322448791.USD","LEGR","IE000BZT7R73.USD","LU1712237335.SGD","LU2860962120.EUR","LU0980610538.SGD","IE000SO60NU8.SGD","BK4528","LU2237443382.USD","LU0359201885.HKD","LU0648001328.SGD","IE00B3CCJ963.GBP","LU0225283273.USD",".DJI","LU1316542783.SGD","ORAC","ORCX","GSID","LINT","LU1323610961.USD","LU0053666078.USD","LU2750360641.GBP","MEMX","BK4516","LU2102340556.USD","BK4554","PJP","LU1983299246.USD","LU0084288322.USD","LU2023251221.USD","LU0082616367.USD","03145","LU1037948897.HKD","LU2462611646.USD","LU1894683348.USD","LU1366192091.USD","XNTK","SG9999013999.USD","SPRX","LU1815333072.USD","LU0289739699.SGD","LU0310799852.SGD","LU0823038988.USD","LU2360107168.USD","LU1571399168.USD","LU0433182093.SGD","LU2237443549.SGD","LU1815336760.USD","LU2462591277.SGD","LU0661504455.SGD","LU0353189680.USD","LU1883866441.USD","CTEX","CNEQ","IE000M9KFDE8.USD","LU0264606111.USD","IE00BKVL7J92.USD","LU0345770308.USD","LU1282649810.SGD","LU1989771016.USD","IE00B66KJ199.SGD","LU2272731865.HKD","LU2468319806.SGD","ASIA","MEDX","LU0300736062.USD","TINS","IE00B19Z3B42.SGD","LU1839511570.USD","LU0719512351.SGD","BK4550","LU0345774631.USD","LU1642822529.SGD","LU1064131342.USD","LU1989764664.SGD","LU2087625088.SGD","LU1868837565.USD","LU1989772923.USD","SGXZ51526630.SGD","LU0823434740.USD","IFLR","LU2089984988.USD","LU0345781412.USD","LU2294711713.HKD","LU1992135472.HKD","LU2357627491.SGD","LU0158827781.USD","IE00BBT3K403.USD","LU0868486357.SGD","LU1934455863.HKD","LU2506952097.USD","IE00B7SZLL34.SGD","LU1935042488.USD","LU0384037296.USD","LU0097036916.USD","LU2242652126.USD","LU2746668461.USD","LU0572940350.SGD","BK4526","QTUP","IE00BGHQF524.EUR","IE00BN8TJ469.HKD","LU1929549753.HKD","LU0795875086.SGD","IE00BZ199S13.USD","BK5113","LU0787776722.HKD","IE00BJJMRZ35.SGD","LU1861215975.USD","TDIV","LU2028103732.USD","LU0210528500.USD","LU1989772840.SGD","CORO","BK4566","LU1582986359.USD","FTXN","SG9999004220.SGD","LU1894683264.USD","SG9999014542.SGD","LU1093756325.SGD","ORCU","LU2129689431.USD","LU1823568750.SGD","PXE","BK4147","PXI","BK4138","BK4532","LU0114720955.EUR","LU0256331488.USD","SPTE","IE00BFXG1179.USD","IE00B3S45H60.SGD","LU0868494617.USD","LU0251132253.USD","LU0823417737.USD","LU0823434583.USD","LU1804176565.USD","LU0056508442.USD","PQNT","LU2148611432.USD","FTXL","EGGY","ORCL","LU0345769128.USD","LU0278409577.USD","LU0266512473.USD","IE000F7OJYX1.SGD","LU2505996681.GBP","LU2458330243.SGD","LU2592432038.USD","LU2125154778.USD","EMM","BK4082","LU0077335932.USD","LU0878004406.USD","TEK","SG9999002521.SGD","LU2896262040.SGD","SG9999014559.SGD","BK4121","LU0965508806.USD","LU1366333091.USD","LU0211328371.USD","SG9999002224.SGD","EFA","LU0210536198.USD","UDOW","LU0068578508.USD","LU2247934214.USD","LU0476273544.USD","LU0143863784.USD","IE00B775SV38.USD","IE00B1BXHZ80.USD","BK4201","LU2487616109.SGD","LU1988902786.USD","WQTM","IE00BKDWB100.SGD","LU2063271972.USD","LU0029874061.USD","IGE","LU2362541513.USD","BK4585","LU0094547139.USD","LU0061474960.USD","LU1674673691.USD","LU0130102774.USD","LU2764262908.HKD","SG9999014575.USD","LU1974910355.USD","TRUN","LU2041044095.USD","LU2298321311.HKD","LU2106854487.HKD","BK4141","SPWO","SGXZ81514606.USD","IEO","LU0648000940.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320908","title":"AI 製藥迎來價值兑現期,創新藥產業打開全新增長空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320908","media":"独角兽智库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320908?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:44","pubTimestamp":1788867840,"startTime":"0","endTime":"0","summary":"AI 制药行业已经走过早期概念炒作阶段,产业验证层级持续向上,从算法叙事正式转向管线价值兑现,行业商业化拐点正在加速到来。随着 AI 制药行业持续发展,生物测序数据需求持续扩张,设备与试剂业务打开增量空间,站在产业链上游充分受益行业整体景气上行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-08/doc-inircmes6042281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","VTHR","MEDX","06978","159992","CHAT","AIPO","BK1191","01477","AGIX","QTOC","BK1574","BK1161","IBBQ","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324003","title":"PHARVARIS的3期臨床試驗達到全部主要及次要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324003?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:53","pubTimestamp":1788864791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","IBBJ","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329150","title":"石藥集團:SYH2083滴眼液獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329150?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:51","pubTimestamp":1788861091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","PSYK","BMED","MDTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329827","title":"膽固醇藥物臨床試驗受挫,數十億美元研發競賽蒙上陰影","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329827","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:33","pubTimestamp":1788859980,"startTime":"0","endTime":"0","summary":"受该消息影响,诺华周一股价下跌 3%。诺华表示完整试验结果将在后续医学学术大会上公布。诺华强调,本次 8000 多名受试者均已接受最优标准治疗。诺华失利,安进与礼来压力陡增此前分析师测算,如果 pelacarsen 临床试验成功,其销售峰值有望达到每年 4050 亿美元。但该临床试验的冲击不止波及诺华一家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inirceww4625928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","PSYK","IBBJ","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665215326","title":"諾華試驗受挫且BMO下調評級,安進股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2665215326","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665215326?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:27","pubTimestamp":1788859661,"startTime":"0","endTime":"0","summary":"BUZZ-诺华试验受挫且BMO下调评级,安进股价下跌9月8日-** 安进公司(AMGN.O)股价盘前下跌4.8%,至416美元** 诺华公司(NOVN.S)的降胆固醇药物在一项备受关注的研究中未能达标,这引发了市场对安进公司(Amgen)实验性降胆固醇药物olpasiran的担忧 (link)** 摩根大通分析师表示,诺华的pelacarsen研究结果降低了市场对安进olpasiran的预期,而该","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T4500MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU0058720904.USD","TBXU","BK4585","SG9999001440.SGD","AMGN","LU0109394709.USD","LU0289739699.SGD","LU0320765992.SGD","LU0868494617.USD","BBH","PJP","BK4581","LU2468319806.SGD","BK4566","IBBQ","LU1571399168.USD","PBE","IBB","BK4534","IE0002141913.USD","BIB","LU0122379950.USD","BK4533","LU1023059063.AUD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU1983299246.USD","LU0889565916.HKD","LU2242652126.USD","IE00B4R5TH58.HKD","LU2112291526.USD","LU1057294990.SGD","BK4139","BK4588","LU2242646821.SGD","IE00B2B36J28.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132698","title":"復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132698","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665132698?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:13","pubTimestamp":1788858794,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药 发布公告,近日,公司控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局关于同意FXS5626片用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。复星医药产业拟于条件具备后于中国境内开展该药品的相关临床研究。截至2026年8月,公司现阶段针对FXS5626的累计研发投入约为1.08亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","02196","IBBQ","BK0188","BMED","IBBJ","BK0175","BK0028","BK0096","PSYK","BK0012","BK1191","BK0187","BK1515","600196","BK0060","BK1593","BK0196","BK0183","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176595225","title":"盤前異動:安進、耐克、Bloom Energy 等個股受關注","url":"https://stock-news.laohu8.com/highlight/detail?id=1176595225","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176595225?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:10","pubTimestamp":1788858632,"startTime":"0","endTime":"0","summary":"安进:这家生物科技巨头、道琼斯指数的重要权重股,其盘前股价重挫逾5%。此前,瑞士制药商诺华宣称,其一款实验性药物在晚期临床试验中未能有效降低心血管风险。安进与礼来目前正在各自研发竞品疗法以应对挑战。消息传出后,诺华在欧股市场大跌10%,礼来股价亦小幅走低。Bloom Energy:这家燃料电池制造商可谓利好连连。受此提振,其盘前股价上扬4%。游戏驿站定于今日美股收盘后发布财报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COYY","07311","WNTR","BK4585","MST","COIA","MSTW","LU0786609619.USD","3SMI.UK","07799","SG9999001440.SGD","FIAT","IE00BFTCPJ56.SGD","LU0128525929.USD","BK4535","IBAT","BLCK","3LMI.UK","LMI3.UK","BK4558","HOYY","LU1057294990.SGD","LU2112291526.USD","LU2360107671.USD","MSTK","CTEC","COIO","HODU","BK4534","BK4561","IAI","09711","BK4007","HOOZ","LU2506951792.HKD","IE00B4R5TH58.HKD","GMEY","BEX","BK4539","BK4581","BK4139","APED","LU1861220207.SGD","LU0444971666.USD","LU0211331839.USD","OWNB","FDIG","BE","LU2468319806.SGD","09399","CONL","LU0310800965.SGD","TBXU","LU1267930573.SGD","MSDD","LU0320765489.SGD","IE0009354923.USD","BK4577","ICLN","BK4127","UPGR","VTWG","IE0002141913.USD","04332","CNRG","BK4596","MSTC","BIB","BK4146","HOOC","ZAP","BPAY","LU1642822529.SGD","IE0009355771.USD","LU1983299246.USD","BITQ","HOOY","LU0289739699.SGD","LU0868494617.USD","NKE","LU0444973449.USD","BK4541","WATS","BK4551","07399","HOOG","BK4532","BK4023","LU1267930813.SGD","LU0823411888.USD","MSII","BK4182","GME","09311","LU0122379950.USD","LU0320765992.SGD","LU0823414478.USD","LU1988902786.USD","SMOG","COII","LU1267930227.SGD","IE00BJJMRZ35.SGD","ROBN","MSTX","AMGN","BEG","CONI","FINX","IBLC","LU2098885051.SGD","MSTU","COIN","IBB","IMST","SMI3.UK","COIG","LU0792757196.USD","LU2264538146.SGD","LU2543165471.USD","NVS","IE00BFXG0V08.USD","LU0476273544.USD","LU2089984988.USD","IE00BJT1NW94.SGD","SIMS","CRPT","IE00B2B36J28.USD","LU1061106388.HKD","COIX","FRNW","LU0058720904.USD","LU0029864427.USD","HOOW","LU2249611893.SGD","HOOI","CONX","GMEU","MSOO","BK4595","LU1023059063.AUD","HOOD","LU1571399168.USD","MSTZ","CONY","LU0957808578.USD","09799","BK4554","BK4516","HOOX","LU0208291251.USD","LU2357125470.USD","IGME","LU1861217088.USD","BEC","BK4533","GMEC","BBH","LU2242646821.SGD","DAPP","LU0310800379.SGD","LU0889566641.SGD","MEDX","MSST","MSTY.UK","LU1064131342.USD","MTYY","STYL","LU1303367103.USD","MSTY","BK4599","IE00BYQQ9H92.USD","HOII","BK4600","MSTP","PBE","BK4588","BK4076","PPH","PJP","BKCH","LU0128525689.USD","07711","LU0070302665.USD","BEZ","BK4566","LU0109394709.USD","LU2294711713.HKD","COIW","LU0823414551.USD","LU0708994859.HKD","LU1815336760.USD","BK4112","LU1861558580.USD","VCLN","LU2242652126.USD","LU0052756011.USD","BK4578","EGGY","BK4547","IBBQ","LU0889565916.HKD","ICOI","LU1861559042.SGD","SMST","MSTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326953","title":"美股異動|安進盤前跌5.4%,諾華同靶點藥物III期臨床失敗,Lp(a)賽道遭重創","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326953","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326953?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:07","pubTimestamp":1788858422,"startTime":"0","endTime":"0","summary":"消息面上,诺华于9月4日公布,其与Ionis联合开发的降脂药物Pelacarsen,在名为LpHORIZON的III期临床试验中未能达到主要终点。诺华的Pelacarsen是全球首个针对Lp靶点进行心血管结局验证的III期药物。因此,市场担忧情绪蔓延到了同样在开发Lp药物的安进身上。多家分析机构认为,诺华的失败削弱了但并未完全推翻Lp这一靶点的可行性。安进后续公布的Olpasiran完整试验数据,将成为判断该靶点未来走向的关键。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/08/20260908512020.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260908/32363493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2242652126.USD","BK4533","LU0122379950.USD","PBE","LU0289739699.SGD","LU0320765489.SGD","IBB","BK4007","SG9999001440.SGD","LU0109394709.USD","IE0009355771.USD","BK4578","LU0208291251.USD","BK4588","BK4599","LU2468319806.SGD","MEDX","IE0002141913.USD","IBBQ","LU0070302665.USD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU1571399168.USD","LU2089984988.USD","TBXU","LU0058720904.USD","BK4585","LU2112291526.USD","AMGN","IE00BJT1NW94.SGD","NVS","LU0320765992.SGD","BK4532","BIB","IE00BJJMRZ35.SGD","BK4566","BK4534","PJP","BK4581","LU1061106388.HKD","LU1983299246.USD","LU1057294990.SGD","LU0211331839.USD","BBH","LU1023059063.AUD","LU0889565916.HKD","PPH","BK4139","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665257563","title":"製藥巨頭諾華股價大跌近10%,遭遇三項藥物臨床試驗受挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2665257563","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665257563?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:50","pubTimestamp":1788857448,"startTime":"0","endTime":"0","summary":"该股最新跌幅达 9.4%。一周之内接连遭遇第三起临床试验挫折,引发投资者抛售,股价或将创下上市以来最差单日交易记录。德尔德西兰临床试验失利数日之前,诺华另一款用于降低心血管事件风险的药物刚在晚期临床试验遇挫;一周前,诺华还宣布,因三名受试者死亡,暂停了实验性细胞疗法 rapcel 的八项临床试验。","market":"us","thumbnail":"http://n.sinaimg.cn/finance/transform/59/w550h309/20260908/d06c-43061a4fc4516fcb77a4d9ff51620de1.png","type":0,"news_type":0,"thumbnails":["http://n.sinaimg.cn/finance/transform/59/w550h309/20260908/d06c-43061a4fc4516fcb77a4d9ff51620de1.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inirceww4608579.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LU0208291251.USD","IBBJ","IE0009355771.USD","IE00B4R5TH58.HKD","LU0211331839.USD","NVS","MDTX","PPH","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0070302665.USD","IE00BJT1NW94.SGD","MEDX","IE00BFTCPJ56.SGD","BK4578","IBBQ","BK4007","LU0320765489.SGD","PSYK","BK4588","BK4585","BK4532","BMED","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665258833","title":"安進股價盤前下跌5.4%;競爭對手諾華的膽固醇藥物後期臨床試驗失敗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665258833","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665258833?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:28","pubTimestamp":1788856084,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4599","BK4588","LU1023059063.AUD","MDTX","TBXU","LU0868494617.USD","IE0002141913.USD","BK4566","IE00BFTCPJ56.SGD","LU1061106388.HKD","PSYK","BK4534","BK4007","LU2089984988.USD","MEDX","LU0122379950.USD","LU2242652126.USD","PBE","PPH","LU0320765992.SGD","NVS","BBH","AMGN","BK4585","IE00BJJMRZ35.SGD","BIB","IBBQ","IBB","BK4533","BK4578","LU0058720904.USD","BK4532","LU0211331839.USD","LU0109394709.USD","LU2112291526.USD","PJP","LU0320765489.SGD","LU1983299246.USD","LU1057294990.SGD","LU0070302665.USD","LU2242646821.SGD","BMED","IE00BJT1NW94.SGD","LU0289739699.SGD","SG9999001440.SGD","LU0208291251.USD","LU0889565916.HKD","IBBJ","BK4581","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323037","title":"邁普醫學(301033.SZ):「可吸收止血流體明膠」進入臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323037","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323037?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:21","pubTimestamp":1788855709,"startTime":"0","endTime":"0","summary":"智通财经APP讯,迈普医学(301033.SZ)发布公告,公司的研发项目“可吸收止血流体明胶”于近期正式进入临床试验阶段。该医疗器械临床用途:在外科手术中,当压迫、结扎、电凝或其他传统的止血方法无法控制小动脉、静脉及毛细血管的出血,或上述方法无法操作时,可使用可吸收止血流体明胶进行辅助止血。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","PSYK","BK0251","301033","IBBJ","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":9,"totalSize":215,"code":"91000000","status":"200"}]}}